# Chemed Corp (CHE) Stock Analysis: Healthcare Leader Offers 23.57% Potential Upside

- Link: https://www.directorstalkinterviews.com/chemed-corp-che-stock-analysis-healthcare-leader-offers-23-57-potential-upside/4121213477
- Published: 2025-08-25T10:25:17+01:00
- Author: Madison Wilson

Chemed Corp (NYSE: CHE) stands out as a key player in the healthcare sector, specifically
within the medical care facilities industry. With a market capitalization of $6.69
billion, Chemed operates two pivotal segments: VITAS, which provides hospice and
palliative care services, and Roto-Rooter, known for plumbing and related services.
Headquartered in Cincinnati, Ohio, and incorporated in 1970, Chemed’s dual business
model offers a unique diversification in its revenue streams.

Currently trading at $459.05, Chemed’s stock has seen a modest price increase of
0.01%, with a 52-week range fluctuating between $412.30 and $619.21. This price 
stability, coupled with a forward P/E ratio of 18.23, suggests a reasonable valuation
considering the company’s growth prospects. Although certain valuation metrics such
as the trailing P/E and PEG ratios are unavailable, the forward P/E provides a glimpse
into market expectations for the company’s future earnings.

Chemed’s performance metrics reveal a revenue growth of 3.80%, an impressive return
on equity of 24.14%, and an EPS of 19.42, underlining its profitability and efficient
use of shareholders’ equity. The company’s robust free cash flow of approximately
$285 million further underscores its financial health and ability to sustain operations
and potential expansion.

Investors with an eye for dividends will note Chemed’s yield of 0.52% and a conservative
payout ratio of 10.29%, indicating a commitment to returning value to shareholders
while retaining capital for growth opportunities.

Analyst sentiment towards Chemed is largely positive, with three buy ratings and
one hold rating, and no sell ratings. The stock’s target price range spans from 
$490.00 to $610.00, with an average target price of $567.25. This positions Chemed
for a potential upside of 23.57%, an attractive prospect for growth-oriented investors.

Technically speaking, Chemed’s stock is slightly below its 50-day moving average
of $474.37 and significantly below its 200-day moving average of $542.58, suggesting
room for upward momentum. The RSI of 55.82 indicates a neutral position, while the
MACD and signal line values (-4.12 and -9.44, respectively) suggest a potential 
for bullish crossover.

Chemed’s dual-focus business model offers both stability and growth potential, making
it an intriguing option for investors looking to diversify within the healthcare
sector. With a strong foothold in essential services, Chemed Corporation continues
to present a compelling investment narrative, bolstered by solid financial metrics
and promising analyst ratings.

Share on:
